Kidney Cancer Research Summit | Conference

Molecular Subtyping and Surgical Sequencing Broaden Immunotherapy Applications in RCC

August 14th 2023

Tian Zhang, MD, discusses unanswered questions regarding molecular drivers of kidney cancer that the OPTIC RCC trial aims to answer, next steps with this research, and the potential benefits of receiving systemic therapy prior to undergoing cytoreductive nephrectomy for patients with metastatic renal cell carcinoma.

Stereotactic Radiation Strategies May Bolster RCC Multi-Modality Management Efforts

August 3rd 2023

Raquibul Hannan, MD, PhD, discusses the benefits of using stereotactic radiation in patients with localized RCC who are unfit for surgery, research findings indicating improved outcomes in patients who received radiation for metastatic disease, and how this radiation technique may work in concert with systemic therapy.

ICI-Treated Synchronous mRCC Is Associated With Negative Survival Outcomes

July 17th 2023

Patients with synchronous metastatic renal cell carcinoma who received first-line immunotherapy had worse survival outcomes compared with those with metachronous metastatic renal cell carcinoma.

ADCs and Radiotherapeutics Represent Novel Treatment Methods in RCC

July 15th 2023

The investigation of treatment regimens featuring antibody-drug conjugates or radiotherapeutics are part of the ongoing wave of research in renal cell carcinoma.

Lenvatinib/Pembrolizumab Benefit Is Upheld in Advanced RCC, Including ICI-Pretreated and Naïve Subgroups

July 14th 2023

The combination of lenvatinib and pembrolizumab continued to show clinical activity in patients with metastatic renal cell carcinoma, including in subsets of patients who had received or were naïve to checkpoint inhibitors.

Tumor Sequencing Identifies Host Signatures Tied to Immunotherapy Response in Advanced RCC

July 14th 2023

Higher levels of baseline TCR clonality in peripheral blood mononuclear cells (PBMCs) and baseline IgG1 fraction in PBMCs and tumor tissue were identified in an institutional cohort of samples from patient with metastatic renal cell carcinoma.

Olaparib Monotherapy Showcases Antitumor Activity in BAP1-mutated RCC

July 14th 2023

Olaparib monotherapy elicited responses with favorable tolerability in patients with renal cell carcinoma whose tumors harbored BAP1 or other DNA repair gene mutations, according to data from the interim analysis of the phase 2 ORCHID trial presented during the 2023 Kidney Cancer Research Summit.

Knowledge Gap Remains for Sequencing of Later-Line Treatments of Advanced RCC

July 14th 2023

Although the use of immunotherapy treatment approaches continues to become more prevalent in advanced renal cell carcinoma, high-level evidence showing benefit of sequential administration of these agents are limited.

Leveraging Biology to Guide First-Line Treatment of Clear Cell RCC

July 14th 2023

Determining the appropriate front-line treatment pathway for patients with clear cell renal cell carcinoma may not always align with risk stratification features.

Dr Lee on Extended Follow-Up With Pembrolizumab and Lenvatinib in Pretreated mRCC

July 14th 2023

Chung-Han Lee, MD, PhD, discusses the final results of the phase 2 cohort of a phase 1/2 trial evaluating lenvatinib plus pembrolizumab in patients with pretreated metastatic clear cell renal cell carcinoma.

Dr Ged on Interim Data With Olaparib in DNA Repair Gene–Mutated mRCC

July 14th 2023

Yasser Mohamed Ali Ged, MBBS, discusses the phase 2 ORCHID trial (NCT03786796).

Dr Choueiri on Trials in Progress in Advanced Renal Cell Carcinoma

July 14th 2023

Toni K. Choueiri, MD, discusses ongoing trials in advanced renal cell carcinoma.

Dr McDermott on the Ongoing LITESPARK-024 Trial in Pretreated Advanced RCC

July 14th 2023

David F. McDermott, MD, discusses the randomized phase 2 LITESPARK-024 trial (NCT05468697).

Frontline Immunotherapy, Delayed Nephrectomy May Allow for Improved Disease Control in mRCC

July 14th 2023

Neoadjuvant immunotherapy–based combinations led to reductions in tumor size and pathologic necrosis at the time of cytoreductive nephrectomy in patients with metastatic renal cell carcinoma.

Adjuvant Pembrolizumab Provides Survival Benefit Across ccRCC Risk Groups and Disease Stages

July 14th 2023

Adjuvant pembrolizumab prolonged disease-free survival and distant metastasis-free survival compared with placebo across The University of California Los Angeles Integrated Staging System–categorized subgroups of patients with clear cell renal cell carcinoma.

Frontline Lenvatinib Plus Pembrolizumab Produces Superior Responses Vs Sunitinib in Advanced RCC

July 14th 2023

Lenvatinib plus pembrolizumab demonstrated improved overall response rates compared with sunitinib monotherapy in treatment-naïve patients with advanced renal cell carcinoma regardless of risk status or PD-L1 expression.

Imaging Mass Cytometry May Identify Therapeutic Targets in ccRCC

July 13th 2023

The tumor-immune evasion cell networks in clear cell renal cell carcinoma may be captured and classified using imaging mass cytometry, an orthogonal approach with the potential for increased cost-efffectiveness and accuracy compared with single-cell RNA sequencing.